Genzyme to present MS drug trials

CAMBRIDGE, Mass. — Drug maker Genzyme plans to present data from trial programs of two multiple sclerosis drugs at the American Academy of Neurology's annual meeting in New Orleans, which starts this Saturday and lasts until next Saturday.

Genzyme, owned by French drug maker Sanofi, will present results of 12 trials of the experimental drugs alemtuzumab and teriflunomide, including the phase-3 "CARE-MS II" trial, which compares alemtuzumab with Rebif (interferon beta-1a), made by Pfizer and Merck KGaA.

"Genzyme's robust development programs for alemtuzumab and teriflunomide were designed to understand how these therapies can best address significant unmet medical needs of people living with MS," Genzyme president and CEO David Meeker said. "We are committed to becoming a long-term partner to the MS community with the goal of raising the expectation of what life with MS can be."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.